CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patientsMabel Hernández-Cedeño, María del Carmen Domínguez-Horta, R Venegas-Rodriguez et al.|Cell Stress and Chaperones|2021Cited by 28
A peptide derived from HSP60 reduces proinflammatory cytokines and soluble mediators: a therapeutic approach to inflammationMaría del Carmen Domínguez-Horta, Gerardo Guillén, Anabel Serrano-Díaz et al.|Frontiers in Immunology|2023Cited by 21
Jusvinza, an anti-inflammatory drug derived from the human heat-shock protein 60, for critically ill COVID-19 patients. An observational studyR Venegas-Rodriguez, María del Carmen Domínguez-Horta, Anabel Serrano-Díaz et al.|PLoS ONE|2023Cited by 7
CIGB-258 immunomodulatory peptide: a novel promising treatment for critical and severe COVID-19 patientsR Venegas-Rodriguez, B Santiesteban-Licea, Ana R. García et al.|medRxiv|2020Cited by 7
Proteomic Profile Regulated by the Immunomodulatory Jusvinza Drug in Neutrophils Isolated from Rheumatoid Arthritis PatientsMabel Hernández-Cedeño, María del Carmen Domínguez-Horta, Arielis Rodríguez‐Ulloa et al.|Biomedicines|2024Cited by 4